Coadministration of WEE1 inhibitors (e.g., adavosertib) and PARP inhibitors (e.g., olaparib) is reported to be effective in inhibiting ovarian tumour growth regardless of BRCA mutation status but poorly tolerated when the compounds are used in their free form due to common overlapping toxic effects [153,154]. This evidence concerns the gene PARP1 and ovarian neoplasm.